Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

TScan Therapeutics Q3 2026 Results: Net Loss of $33.1M, Loss Narrows

TScan Therapeutics reports significant ongoing losses and has identified conditions raising substantial doubt about its ability to continue as a going concern. The company is currently non-compliant with Nasdaq's continued listing requirements and requires substantial additional funding to advance its TCR-T therapy product candidates through clinical development.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.62.5
Net income-33.1-35.7
EPS (diluted, $ a share)$-0.25$-0.28

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-76.7%
Source

10-Q filed with the SEC, NASDAQ: TCRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

TScan Therapeutics, Inc.: key numbers

Share price
$0.1451Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from TScan Therapeutics, Inc.

All →
7:01 AM ET 8-K
Financial Results

TScan Therapeutics Financial Results

TScan Therapeutics reported third quarter 2026 financial results and announced a strategic reorganization to prioritize its in vivo-engineered TCR-T cell therapy program for solid tumors. The company has paused enrollment in its Phase 3 ALLOHA-2 study for heme malignancies to conserve capital and is actively seeking strategic partners for its heme and autoimmunity programs.

“This quarter marked an important step in accelerating TScan’s solid tumor program. We are concentrating all our efforts on our in vivo-engineered TCR-T cell approach for solid tumor indications, where we see an opportunity to bring an exciting new treatment modality to patients in desperate need of better treatment options.”

Gavin MacBeath, Ph.D., Chief Executive Officer
4:45 PM ET 8-K
Leadership Change

TScan Therapeutics Leadership Change

Garry Nicholson and Gabriela Gruia, M.D., resigned from the Board of Directors of TScan Therapeutics effective October 13, 2026. The company stated the resignations were not due to any disagreements and announced the appointment of Stephen Biggar and R. Keith Woods to the Nominating and Corporate Governance Committee to fill the vacancies.

5:00 PM ET 8-K
Executive Compensation

TScan Therapeutics Executive Compensation

TScan Therapeutics entered into separation agreements with its outgoing CFO, Jason A. Amello, and CMO, Dr. Chrystal Louis, following a strategic reorganization. The agreements provide for continued salary and benefits through November 1, 2026, and include potential milestone-based cash awards of $85,000 and $125,000, respectively, under a 2025 retention program.

Counterparty
Jason A. Amello and Chrystal Louis, M.D., MPH
Term
through Nov 1, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.